At a Glance
Balaji Amines Ltd (BAL), India’s king of aliphatic amines, delivered Q1 FY26 numbers that scream “meh” to investors. Revenue inched up to ₹358 Cr (+2% QoQ) while net profit slipped 15% YoY to ₹37 Cr, dragging OPM to 15%. Stock has already shed 31% YoY, proving the market’s love affair with specialty chemicals is over faster than a Tinder date gone wrong. On the bright side, the company is almost debt-free and still pays a dividend. On the dark side, growth is MIA, margins are sulking, and global chemical prices aren’t helping.
Introduction
There was a time when Balaji Amines was the darling of specialty chemical investors. High margins, robust demand from pharma and agrochemicals, and a clean balance sheet – what’s not to love? Fast forward to FY26, and the company looks like it’s stuck in a hangover.
Prices of key products have softened, exports are under pressure, and operational leverage isn’t kicking in. Revenue has been in a slow decline, and profits have been dropping faster than Bollywood’s creativity. With the stock at ₹1,692 (P/E 36.8), investors are questioning if this is still a growth story or just an expensive midlife crisis.
Business Model (WTF Do They Even Do?)
Balaji Amines is India’s largest manufacturer of aliphatic amines and their derivatives – chemicals used in pharma, pesticides, and solvents. If you’ve taken a pill, sprayed insecticide, or
